Study guide
12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
Key Takeaways Explain This Topic AI
Type of First Recurrence [1880] records the first recurrence after a documented disease-free period; once a recurrence (04–62 or 88) is recorded, later recurrences are not recorded.
Code 70 means the patient was never disease-free, including distant metastasis at diagnosis, systemic disease, unknown primary, or untreated minimal disease; if the patient later becomes disease-free, change 70 to 00 and keep following.
Codes 13, 22, 52 and 62 are common: 13 local recurrence of an invasive tumor, 22 regional lymph nodes only, 52 lung only, 62 distant recurrence in multiple site categories.
Recurrence codes for tumors first diagnosed in situ are limited to 06, 16, 17, 26, 27, 36 and 46; codes 00, 88 and 99 apply to any tumor.
Leukemia or lymphoma in remission is coded 00, and a relapse is coded 59; whether a later tumor is a recurrence or a new primary is decided by the Solid Tumor Rules or the Hematopoietic manual, not by the physician's wording alone.
Last updated: September 2026
Recurrence definitions (STORE)
Type Definition
Local Recurs in the initial primary organ, including the remnant of the organ, the anastomosis, or the scar where the organ was
- Trocar The organ was removed and the tumor recurs in the trocar path or entrance site
- Regional Recurs in adjacent tissue or organs, or in the lymph nodes draining the organ
- Distant Recurs in a location beyond regional
A recurrence requires a documented disease-free period first. Growth of disease that never went away is progression or persistence , not recurrence.
Date of First Recurrence [1860]
Record the date the physician diagnoses the first progression, metastasis or recurrence after a disease-free period .
It is transmitted as CCYYMMDD, with blanks for unknown parts or when not applicable (for example, a patient with no recurrence).
Type of First Recurrence [1880]: the code families
- Codes Meaning
- 00 Became disease-free after treatment and has not had a recurrence
- 04 In situ recurrence of an invasive tumor
- 06 In situ recurrence of an in situ tumor
- 10 Local recurrence, not enough information for 13–17
- 13 Local recurrence of an invasive tumor
- 14 Trocar recurrence of an invasive tumor
- 15 Both local and trocar (13 + 14)
- 16 / 17 Local, or local and trocar, recurrence of an in situ tumor
- 20 Regional recurrence, not enough information for 21–27
- 21 Invasive, adjacent tissue or organs only
- 22 Invasive, regional lymph nodes only
- 25 Invasive, both adjacent tissue and regional nodes (21 + 22)
- 26 / 27 Regional recurrence of an in situ tumor (NOS, or adjacent plus nodes)
- 30 Invasive regional (20–25) and local or trocar (10–15)
- 36 In situ regional (26–27) and local or trocar (16–17)
- 40 Distant recurrence to a site not listed in 46–62, or not enough information
- 46 Distant recurrence of an in situ tumor
- 51 Peritoneum only (includes positive ascitic fluid)
- 52 Lung only (includes visceral pleura)
- 53 Pleura only (includes positive pleural fluid)
- 54 Liver only
- 55 Bone only (bones other than the primary site)
- 56 CNS only (brain and spinal cord, not the external eye)
- 57 Skin only (other than the primary site)
- 58 Distant lymph nodes only
- 59 Distant systemic: lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease
- 60 A single distant category (51–58) plus local, trocar or regional recurrence
- 62 Multiple distant categories (for example, liver, lung and bone)
- 70 Never disease-free since diagnosis
- 88 Recurred, type unknown
- 99 Unknown whether recurred or ever disease-free
- Coding rules
Hierarchy: codes 00–70 are hierarchical, so record the highest-numbered applicable code, within these limits:
The first time a patient goes from 70 (disease) to disease-free , change the code to 00 .
The first time a patient goes from 00 to a recurrence , record the recurrence code.
No further changes after that, other than corrections.
Only the first recurrence counts. Later recurrences are not recorded.
In situ primaries use only 06, 16, 17, 26, 27, 36 or 46 for recurrence. Codes 00, 88 and 99 can apply to any tumor.
Codes 51–59 apply only when all first distant recurrences fall in one category. Multiple metastases within one organ (for example, several liver nodules) are still one category.
Hematopoietic: leukemia or lymphoma in remission is 00 . A relapse is 59 . Disease controlled by drugs (STORE's example is imatinib for CML) counts as remission.
Two primaries, recurrence of unknown origin: if the physician cannot tell which primary recurred, code the recurrence on each tumor, and revise when the origin is known.
Recurrence versus new primary: STORE tells registrars to check the Solid Tumor Rules (or earlier MP/H rules) to decide which later tumors are recurrences. A physician's word "recurrence" does not decide it. For example:
The breast rules make a tumor diagnosed more than five years after the patient was clinically disease-free a new primary .
The colon rules make a later tumor a new primary when the patient was clinically disease-free for more than one year (rule M10). Tumors at the anastomosis have their own rules (M7 and M8), based on a 36-month interval and whether the tumor arises in the mucosa (Section 14.2).
Follow-up duties for recurrence
Code 70, still in treatment: keep checking at follow-up for a later disease-free status, which may come after second-course therapy.
Code 00: keep following until a recurrence occurs, however long that takes.
Once 04–62 or 88 is recorded, the recurrence items are final. Cancer Status [1770] continues to be updated from physician sources.
Standard 6.5 asks the cancer committee to monitor unknown values in Date of First Recurrence, Type of First Recurrence and Cancer Status.
Worked examples
- Scenario Code
- Stage II colon cancer resected; CT two years later shows liver metastases only 54
Breast cancer after lumpectomy; recurrence in the same breast and axillary nodes at the same time 30 (local 13 plus regional 22)
Lung cancer with a solitary adrenal metastasis at diagnosis, treated with chemotherapy, stable disease 70
Kidney cancer after nephrectomy; recurrence in the renal fossa where the kidney was 13 (scar tissue where the organ was = local)
- Colon cancer; recurrence in liver, lung and bone 62
- Melanoma of the back; later metastases in distant skin only 57
- Follicular lymphoma in remission after chemotherapy, then relapse 59 (was 00 during remission)
- Recurrence documented, but the record says only "recurrent disease" 88